GlassScriptPhysician profile
William A Mills
NPI 1588658330
$11,514.90
in general payments reported to CMS, 2019-2025
54 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,337 · 2020: $1,459 · 2021: $1,340 · 2022: $1,587 · 2023: $1,655 · 2024: $1,493 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,792.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.96 | 2019-2025 | |
| Novo Nordisk INC | $1,223.40 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $880.87 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $798.76 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $781.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $728.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $707.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Sanofi-Aventis U.S. LLC | $593.84 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.63 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.55 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $312.72 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $287.33 | 2019-2024 | Xarelto |
| Amgen INC. | $237.55 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $228.80 | 2022-2025 | |
| Nevro Corp. | $221.58 | 2019 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.